Skip to main content
Clinical Trials/ISRCTN17050221
ISRCTN17050221
Active, Not Recruiting
N/A

euroMuscular Electrical Stimulation for the treatment of Diabetic Neuropathy: A multi-centre, double-blind, pilot, randomised, sham-controlled trial (NMES-DN)

Imperial College London0 sites100 target enrollmentJune 30, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Patients with diabetic neuropathy
Sponsor
Imperial College London
Enrollment
100
Status
Active, Not Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 30, 2023
End Date
September 30, 2025
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged \=18 (no upper limit)
  • 2\. Diagnosis of type 1 or type 2 diabetes based on World Health Organisation (WHO) definition
  • 3\. Diagnosis of diabetic neuropathy based on:
  • 3\.1\. Symptoms of diabetic neuropathy
  • 3\.2\. Validated screening questionnaire Michigan Neuropathy Screening Instrument score of \=4
  • 3\.3\. Nerve conduction study of at least one lower limb must have a sural sensory nerve action potential (SNAP) amplitude of \<6 µV or absent
  • 4\. Access to the internet at home to use the Revitive App (study smartphones will be provided)
  • 5\. Personal mobile phone to receive text messages

Exclusion Criteria

  • 1\. Lacks the capacity to provide informed consent
  • 2\. Pregnant
  • 3\. Implanted electronic, cardiac or defibrillator device
  • 4\. Other causes of peripheral neuropathy (e.g. excessive drinking, low levels of vitamin B12 or other vitamins, syphilis, HIV, underactive thyroid gland)
  • 5\. Current foot ulceration
  • 6\. Severe vascular disease requiring invasive intervention
  • 7\. Being treated for, or having the symptoms of, an existing deep vein thrombosis (DVT)
  • 8\. Used a neuromuscular electrical stimulation (NMES) device within 1 year of randomisation

Outcomes

Primary Outcomes

Not specified

Similar Trials